Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
Efficacy and Tolerability Study of Avanafil in Russia
- Conditions
- Sexual Function and Fertility Disorders NEC-Erectile Dysfunction
- Interventions
- Drug: placebo
- First Posted Date
- 2015-07-20
- Last Posted Date
- 2016-03-17
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 189
- Registration Number
- NCT02503306
To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of a Single Dose Regimen of Ferroquine and Artefenomel in Adults and Children With Uncomplicated Plasmodium Falciparum Malaria
- Conditions
- Plasmodium Falciparum Infection
- Interventions
- First Posted Date
- 2015-07-14
- Last Posted Date
- 2022-03-24
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 377
- Registration Number
- NCT02497612
- Locations
- 🇧🇫
Investigational Site Number 854001, Ouagadougou, Burkina Faso
🇬🇦Investigational Site Number 266001, Libreville, Gabon
🇻🇳Investigational Site Number 704003, Binh Phuoc, Vietnam
Cabazitaxel Versus the Switch to Alternative AR-targeted Agent (Enzalutamide or Abiraterone) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Previously Treated With Docetaxel and Who Rapidly Failed a Prior AR-targeted Agent
- Conditions
- Prostate Cancer Metastatic
- Interventions
- First Posted Date
- 2015-06-30
- Last Posted Date
- 2022-05-27
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 255
- Registration Number
- NCT02485691
- Locations
- 🇧🇪
Investigational Site Number 056007, Brussels, Belgium
🇧🇪Investigational Site Number 056005, Leuven, Belgium
🇫🇷Investigational Site Number 250010, Clermont Ferrand, France
Safety, Tolerability, and Effect of Alirocumab in High Cardiovascular Risk Patients With Severe Hypercholesterolemia Not Adequately Controlled With Conventional Lipid-modifying Therapies (ODYSSEY APPRISE)
- Conditions
- Hypercholesterolemia
- Interventions
- Drug: placebo (for injection training only)
- First Posted Date
- 2015-06-19
- Last Posted Date
- 2022-03-28
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 998
- Registration Number
- NCT02476006
- Locations
- 🇦🇹
Investigational Site Number 040001, Graz, Austria
🇦🇹Investigational Site Number 040002, Wien, Austria
🇦🇹Investigational Site Number 040010, Wien, Austria
A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: Insulin glargine, 300 U/mlDrug: Insulin glargine, 100 U/mlDrug: Background Therapy
- First Posted Date
- 2015-05-21
- Last Posted Date
- 2019-09-10
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 3304
- Registration Number
- NCT02451137
- Locations
- 🇺🇸
Investigational Site Number 840371, Los Angeles, California, United States
🇺🇸Investigational Site Number 840779, Cleveland, Ohio, United States
🇺🇸Investigational Site Number 840348, Pittsburgh, Pennsylvania, United States
Combination of Cabazitaxel With Prednisolone With Primary Prophylaxis With PEG-G-CSF in Treatment of Patients With Prostate Cancer
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2015-05-12
- Last Posted Date
- 2017-01-24
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 21
- Registration Number
- NCT02441894
- Locations
- 🇯🇵
Investigational Site Number 392008, Kita-gun, Japan
🇯🇵Investigational Site Number 392001, Shinjuku-ku, Tokyo, Japan
🇯🇵Investigational Site Number 392004, Chuo-ku, Chiba, Japan
A Study Assessing Efficacy and Safety of SAR125844 in NSCLC Patients With MET Amplification
- First Posted Date
- 2015-05-06
- Last Posted Date
- 2016-03-23
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 1
- Registration Number
- NCT02435121
- Locations
- 🇧🇪
Investigational Site Number 056001, Edegem, Belgium
Evaluation of Dupilumab in Patients With Persistent Asthma (Liberty Asthma Quest)
- Conditions
- Asthma
- Interventions
- Drug: PlaceboDrug: Inhaled corticosteroid (ICS) therapyDrug: Albuterol/SalbutamolDrug: Levalbuterol/Levosalbutamol
- First Posted Date
- 2015-04-13
- Last Posted Date
- 2018-10-23
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 1902
- Registration Number
- NCT02414854
- Locations
- 🇯🇵
Investigational Site Number 392168, Uozu-Shi, Japan
🇺🇸Investigational Site Number 840011, Los Angeles, California, United States
🇺🇸Investigational Site Number 840021, San Jose, California, United States
Multiple Ascending Dose Study in Healthy Male Subjects and Overweight to Obese Male and Female Type 2 Diabetes Mellitus (T2DM) Patients
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2015-04-08
- Last Posted Date
- 2018-06-15
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 76
- Registration Number
- NCT02411825
- Locations
- 🇩🇪
Investigational Site Number 276001, Berlin, Germany
Single-dose Study to Describe the Safety of Sarilumab and Tocilizumab in Patients With Rheumatoid Arthritis
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2015-03-31
- Last Posted Date
- 2016-03-28
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 30
- Registration Number
- NCT02404558
- Locations
- 🇯🇵
Investigational Site Number 392001, Sendai-Shi, Japan
🇯🇵Investigational Site Number 392002, Sendai-Shi, Japan
🇯🇵Investigational Site Number 392003, Sendai-Shi, Japan